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SARCOMA Olaratumab — really a breakthrough for soft-tissue sarcomas?  
Ian Judson and Winette T. van der Graaf 
In a recent study, the addition of olaratumab to doxorubicin chemotherapy for 
patients with soft-tissue sarcoma resulted in prolongation of progression-free survival 
by only 2.5 months, but an overall survival benefit of 11.8 months; the large disparity 
between these outcomes raises important questions. We discuss these results in 
relation to those of other trials, and the implications for sarcoma therapy.  
Refers to Tap, W. D. et al. Olaratumab and doxorubicin versus doxorubicin alone for 
treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 
trial. Lancet http://dx.doi.org./10.1016/S0140-6736(16)30587-6 (2016). 
In the past 20 years, important breakthroughs have been made in the treatment of 
soft-tissue sarcoma (STS), and none more clinically significant than the introduction 
of effective tyrosine kinase inhibitors for patients with gastrointestinal stromal 
tumours with activating mutations in KIT or PDGFRA1. Such advances have, 
however, proved to be the exception rather than the rule: subsequently, few clinical 
studies have demonstrated a survival benefit with experimental therapies. 
Nevertheless, a report published in June 2016 by Tap et al.2 seems to herald a major 
therapeutic breakthrough. In this open-label phase Ib and randomized phase II trial 
involving adults with advanced-stage STS, combination therapy comprising 
doxorubicin and olaratumab, a monoclonal antibody that inhibits PDGFRα, was 
compared with doxorubicin monotherapy — the current standard of care; in the 
phase II part of the study, 133 patients were randomized in a 1:1 ratio2. Patients in 
the combination arm had a median overall survival of 26.5 months, compared with 
14.7 months for those treated with doxorubicin monotherapy (hazard ratio (HR) 0.46; 
P = 0.0003)2. By contrast, PFS was extended by only 2.5 months in the olaratumab 
arm (6.6 months versus 4.1 months)2. Thus, the primary end point of the study, a 
50% increase in PFS, was met, but this improvement was not conventionally 
significant by investigator assessment (HR 0.67; P = 0.0615), or independent 
radiological review (HR 0.67; P = 0.1208)2.  
Interestingly, just 2 months earlier, in April 2016, results of phase III trial of eribulin 
versus dacarbazine in patients with leiomyosarcoma or liposarcoma demonstrated a 
2-month median overall survival benefit for the eribulin cohort (13.5 months versus 
11.5 months; HR 0.77; P = 0.0169), with no difference in the median PFS 
(2.6 months in both groups; HR 0.88; P = 0.23)3. Eribulin treatment mainly benefitted 
the patients with liposarcoma (HR 0.51), with limited or no benefit in patients with 
leiomyosarcoma (HR 0.93). As a result, eribulin has been approved by the US Food 
and Drugs Administration (FDA) and the European Medicines Agency (EMA) for the 
treatment of liposarcoma. Nevertheless, without a prolongation of PFS, no clear 
explanation is available for the overall survival benefit associated with eribulin. 
Conversely, many studies in patients with STS have demonstrated PFS 
improvements, but no increase in overall survival4,5. Similarly, large phase III trials 
have failed to confirm therapeutic benefits seen in randomized phase II studies, 
including unpublished studies of palifosfamide and evofosfamide6,7. Various 
explanations for the lack of an overall survival benefit have been proposed, not least 
the effects of post-protocol treatment. 
Why are trial results so inconsistent in STS? In particular, what factors underlie the 
considerable disparities between the observed PFS and overall survival benefits? An 
answer might lie in the sheer diversity of STS diagnoses: this disease can be 
classified into 70 different histological subtypes8, and this huge heterogeneity 
creates major problems when designing and interpreting clinical trials. In a small trial 
(n = <200), imbalances in disease biology between treatment groups can have major 
effects on the findings, potentially resulting in an apparently major benefit that will not 
subsequently be confirmed in a larger, well-balanced phase III trial. Could this 
phenomenon have occurred in the olaratumab study? Some imbalances did exist: for 
example, the proportion of patients with undifferentiated pleomorphic sarcoma, an 
aggressive STS subtype, was 15% in the combination arm, but 21% in the 
monotherapy arm2. Moreover, more women were included in the combination arm 
(61% versus 51%)2, perhaps indicating an excess of patients with uterine 
leiomyosarcoma. Leiomyosarcoma is itself a heterogeneous group of diseases, 
within which uterine leiomyosarcoma has a relatively good prognosis9. A marked 
imbalance also occurred in the ‘other’ disease category, which included 17 patients 
(26%) in the combination arm, but only six patients (9%) in the monotherapy arm2. 
Importantly, a number of ‘other’ disease subtypes associated with indolent behaviour 
and prolonged survival were represented in the combination arm, but not the 
monotherapy arm, including alveolar soft part sarcoma, endometrial stromal 
sarcoma, extraskeletal myxoid chondrosarcoma, fibrosarcomatous change in 
dermatofibrosarcoma protuberans, solitary fibrous tumour, and myxoid 
chondrosarcoma. These imbalances might have had a substantial effect on overall 
survival. 
Can explanations be drawn from the study design? Tap et al.2 randomly assigned 
patients to receive eight 21-day cycles of doxorubicin given at 75 mg/m2 on day 1, 
with or without olaratumab at 15 mg/kg on days 1 and 15. In the combination arm, 
patients with stable disease response or a better could continue on olaratumab after 
stopping doxorubicin, whereas patients initially assigned doxorubicin monotherapy 
could only receive olaratumab after disease progression. A potential bias in favour of 
continuing treatment with the novel combination was also evident: 21 patients 
discontinued treatment for radiological disease progression in the combination arm, 
but only 12 other patients stopped treatment early2; by contrast, although 27 patients 
in the monotherapy arm discontinued treatment for radiological progression and six 
for symptomatic progression, remarkably, 27 patients stopped treatment early for a 
variety of other reasons2. Indeed, only 7% of patients discontinued combination 
therapy compared with 13% who discontinued monotherapy.  This difference in 
frequency of termination of study treatment for reasons other than disease 
progression occurred in spite of the combination regimen being more toxic, with a 
higher incidence of grade ≥3 adverse effects (80% versus 69%), including bone 
marrow toxicity, nausea, cardiac dysfunction, and decreased appetite2. A potential 
explanation is that patients in the combination treatment arm knew they were 
receiving a potentially effective experimental agent and were reluctant to stop 
treatment. In addition, olaratumab therapy upon disease progression after 
doxorubicin monotherapy was considerably shorter in duration than maintenance 
treatment after combination therapy (median of four versus nine cycles)2. Of note, 
crossover to olaratumab monotherapy after disease progression was reported under 
the category of ‘other’ post-treatment therapy, despite being permitted in the protocol 
and, more importantly, despite the experimental nature of this treatment2. Following 
protocol therapy, patients in the combination arm were almost twice as likely to 
receive gemcitabine plus docetaxel than those in the monotherapy arm, and were 
more likely to receive pazopanib and trabectedin2 — all of which are known to be 
active second-line treatments. As mentioned previously, effective post-trial therapy 
can negate an overall survival advantage; however, post-protocol therapy can also 
lead to an imbalance in favour of the experimental treatment if a systematic bias 
results in crossover of patients in the control arm to an experimental treatment that is 
less effective as monotherapy than subsequent chemotherapy. Thus, the differences 
in post-protocol therapy are potentially important, considering that many patients in 
the doxorubicin arm initially received second-line olaratumab monotherapy, which 
only modestly improves PFS even when combined with doxorubicin in the first-line 
setting2, and were less likely to receive second-line treatments with proven 
effectiveness than those in the combination arm. Finally, no statement is made by 
Tap et al.2 about post-protocol local treatments, such as surgery and radiotherapy, 
that are relatively commonly applied in patients with STS, and might have influenced 
the results. 
Another imbalance, which almost certainly occurred by chance, was the number of 
deaths that were recorded as neither drug-related nor categorically related to 
disease progression: six in the doxorubicin arm, but none in the combination arm.  
 
The precise mechanism of action of olaratumab remains unknown. Interestingly, Tap 
et al.2 found no correlation between tumour PDGFRα positivity and outcome 
(HR 0.64 95% CI 0.31–1.33), and, indeed, reported that negative expression was 
favourable (HR 0.40 95% CI 0.21–0.73)2, which does not support PDGFR inhibition 
in the tumour as the prime mechanism of action. As they discussed, however, the 
immunohistochemistry assay used to assess PDGFRα expression was, in hindsight, 
not very specific and needs improvement. The authors hypothesized that the 
disparity between the PFS and overall survival benefit indicates that the drug could 
induce a persisting alteration in tumour–stromal interactions, but that is currently 
sheer speculation. This result is, nevertheless, reminiscent of findings with 
immunomodulatory therapy: a similar discrepancy between PFS and overall survival 
has been reported with use of the immune- checkpoint inhibitor ipilumumab in 
patients with melanoma10. In that study, prolonged survival was seen in a substantial 
proportion of patients in spite of early radiological disease progression10. Does 
olaratumab possibly exert an immunological effect? Translational studies to explore 
such mechanisms of action, and others, would be useful.  
In conclusion, the findings of this relatively small trial of olaratumab, although 
promising, raise a number of questions, especially regarding the large discrepancy 
between PFS and overall survival. Differences in treatment duration for reasons 
other than radiological progression, imbalances both in histological subtypes and 
post-protocol therapy, and deaths due to unrelated adverse events could all have 
contributed to the result. Eli Lilly have been granted ‘Priority Review’ status for 
olaratumab by the FDA and the agent is currently being reviewed by the EMA under 
an accelerated assessment schedule. What that actually means in terms of access 
of patients with sarcoma to the drug is currently unclear, but provisional approval 
could be granted. What is undoubtedly the case is that the real value of olaratumab 
in the treatment of STS will only be known once the results of the phase III trial of 
this agent, which is currently close to completion (NCT02451943), are published in a 
few years’ time.  
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